Journal articleEur Rev Med Pharmacol Sci2020
Development and validation of an individualized nomogram for predicting pancreatic adenocarcinoma-specific survival: a SEER population analysis of 5,805 patients.
- Journal
- Eur Rev Med Pharmacol Sci
- Published
- 1 October 2020
- Citations
- 10
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Objective A model to predict the overall survival (OS) of pancreatic adenocarcinoma (PAC) is required in consideration of its inferior prognosis. Patients and methods The patients diagnosed with pancreatic cancer between 1975 and 2016 in the Surveillance, Epidemiology, and End Results (SEER) database was used as raw data. … Excerpt only: this text is the publisher’s. Read it in full at the source.